Insulinotropic actions of exendin-4 and glucagon-like peptide-1 in vivo and in vitro

Metabolism: Clinical and Experimental
D G ParkesA A Young

Abstract

This study compares in vitro effects of exendin-4 and glucagon-like peptide (GLP)-1 on basal and glucose-stimulated insulin release from isolated rat islets and in vivo insulinotropic actions of exendin-4 and GLP-1 after an intravenous glucose challenge in rats. In static incubation of isolated islets, changing ambient glucose concentration from 3 mmol/L to 10 mmol/L stimulated insulin secretion 9.8 +/- 1.3-fold. The addition of exendin-4 or GLP-1 (1 nmol/L to 1 micromol/L) increased glucose-stimulated insulin secretion up to 5.8 +/- 1.6-fold and 3.3 +/- 1.0-fold, respectively, over basal rates (defined as no hormones added, 3 mmol/L glucose) and 19.6 +/- 2.3-fold and 15.0 +/- 3.1-fold at 10 mmol/L glucose. In dynamically perfused isolated islets exposed to 7.5 mmol/L glucose, insulin secretion increased 6.4 +/- 1.5-fold, and exendin-4 (20 nmol/L) or GLP-1 (20 nmol/L) increased this similarly by up to 13.5 +/- 2.8 and 12.7 +/- 3.9-fold,respectively. Anesthetized rats administered 5.7 mmol/kg intravenous glucose increased plasma insulin concentration 3.0-fold. Infusion of exendin-4 or GLP-1 increased this to a maximum of 7.6-fold and 5.3-fold, respectively. As with isolated islet studies, in vivo dose responses and concentration...Continue Reading

Citations

Dec 20, 2011·Pharmaceutical Research·Yanguang CaoWilliam J Jusko
Dec 12, 2012·Pharmaceutical Research·Ting ChenLeonid Kagan
Nov 22, 2012·Proceedings of the National Academy of Sciences of the United States of America·Andrea KirkpatrickWilliam A Goddard
Aug 21, 2007·Diabetes Technology & Therapeutics·Patric NelsonMark Fineman
Jun 28, 2006·Diabetes Technology & Therapeutics·David M KendallDavid Maggs
Feb 18, 2012·Drug Metabolism and Disposition : the Biological Fate of Chemicals·Wei Gao, William J Jusko
Dec 16, 2010·The Journal of Pharmacology and Experimental Therapeutics·Wei Gao, William J Jusko
Mar 4, 2010·American Journal of Physiology. Endocrinology and Metabolism·Diego Pérez-TilveFederico Mallo
May 22, 2008·American Journal of Physiology. Endocrinology and Metabolism·Viorica IonutRichard N Bergman
Oct 23, 2009·American Journal of Physiology. Regulatory, Integrative and Comparative Physiology·Elisabeth L RaabRebecca A Simmons
Jan 25, 2013·Journal of Molecular Endocrinology·Ozlem ErdogduThomas Nyström
Feb 27, 2007·Vascular Health and Risk Management·Catherine A SchnabelOrville Kolterman
Oct 3, 2012·Journal of Pregnancy·Noelle Ma, Daniel B Hardy
Mar 23, 2006·Medizinische Monatsschrift für Pharmazeuten·Annemarie Musch, Susanne Heinzl
Oct 6, 2006·Expert Opinion on Pharmacotherapy·Anthony H StonehouseDavid M Kendall
Jul 12, 2005·Expert Opinion on Investigational Drugs·Octaviano A RogesAthena Philis-Tsimikas
Aug 15, 2014·Expert Opinion on Drug Discovery·Mikkel ChristensenFilip K Knop
May 26, 2006·Expert Opinion on Pharmacotherapy·Mariele Briones, Mandeep Bajaj
Feb 27, 2009·Expert Opinion on Investigational Drugs·James MaloneDavid M Kendall
Sep 21, 2013·Expert Opinion on Drug Discovery·Maliheh SafaviMohammad Abdollahi
Jan 26, 2008·Current Medical Research and Opinion·Leonard C GlassRichard M Bergenstal
Dec 29, 2006·Diabetes·Diego Pérez-TilveFederico Mallo
Oct 27, 2004·Diabetes Care·John B BuseUNKNOWN Exenatide-113 Clinical Study Group
Nov 25, 2004·The Annals of Pharmacotherapy·Scott V JoyAnn C Scates
Apr 30, 2005·Trends in Endocrinology and Metabolism : TEM·Polly A Hansen, John A Corbett

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cardiovascular Biology of GLP-1

Glucagon-like peptide 1 (GLP-1) plays a role in glucose metabolism, energy homeostasis, and inflammation suppression. GLP-1 receptor signaling has been shown to impact cardiovascular function. This feed focuses on the role of GLP-1 and GLP-1 receptor agonists on cardiovascular biology.